Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
New breast cancer treatment method sees success in New York trial
A new combination therapy for triple-negative breast cancer (TNBC) showed promising results in Phase I clinical trials, with 66% of patients achieving remission. Conducted by Roswell Park Comprehensive Cancer Center, the therapy involved neoadjuvant chemotherapy and a chemokine modulatory regimen (CKM) with paclitaxel and rintatolimod, interferon alfa-2b, and celecoxib, resulting in no immune-related adverse events. The study concluded that the regimen was safe and effective, with findings published in the British Medical Journal.
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type
New TNBC treatment at Roswell Park achieves 66% complete remission without immune-related adverse events, using a combination of chemotherapy and immunotherapy.
FDA Approval of Trodelvy Withdrawn for Urothelial Carcinoma
Gilead Sciences withdrew FDA accelerated approval of Trodelvy for locally advanced or metastatic urothelial carcinoma, based on TROPiCS-04 study not meeting primary endpoint of overall survival. This withdrawal does not affect other Trodelvy indications.
Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month
Breast Cancer Awareness Month emphasizes early detection, personalized treatment, and addressing disparities. Personalized medicine uses NGS testing and targeted therapies like capivasertib. HER2 ultra-low classification expands T-DXd eligibility. Research aims to reduce treatment toxicities, especially in Black women. Early detection strategies include mammograms and recognizing symptoms. Post-treatment care focuses on regular oncologist visits and managing long-term AEs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath